prikaz prve stranice dokumenta Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting
  Preuzmi
PDF 992.36 KB
Znanstveni rad - Izvorni znanstveni rad
Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting
American Journal of Cardiology, 113 (2014), 10; 1660-1667. https://doi.org/10.1016/j.amjcard.2014.02.024
Gašparović, Hrvoje; Petričević, Mate; Kopjar, Tomislav; Đurić, Željko; Svetina, Lucija; Biočina, Bojan

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Gašparović, H., Petričević, M., Kopjar, T., Đurić, Ž., Svetina, L. i Biočina, B. (2014). Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting. American Journal of Cardiology, 113. (10), 1660-1667. doi: 10.1016/j.amjcard.2014.02.024

Gašparović, Hrvoje, et al. "Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting." American Journal of Cardiology, vol. 113, br. 10, 2014, str. 1660-1667. https://doi.org/10.1016/j.amjcard.2014.02.024

Gašparović, Hrvoje, Mate Petričević, Tomislav Kopjar, Željko Đurić, Lucija Svetina i Bojan Biočina. "Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting." American Journal of Cardiology 113, br. 10 (2014): 1660-1667. https://doi.org/10.1016/j.amjcard.2014.02.024

Gašparović, H., et al. (2014) 'Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting', American Journal of Cardiology, 113(10), str. 1660-1667. doi: 10.1016/j.amjcard.2014.02.024

Gašparović H, Petričević M, Kopjar T, Đurić Ž, Svetina L, Biočina B. Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting. American Journal of Cardiology [Internet]. 15.05.2014. [pristupljeno 26.12.2024.];113(10):1660-1667. doi: 10.1016/j.amjcard.2014.02.024

H. Gašparović, M. Petričević, T. Kopjar, Ž. Đurić, L. Svetina i B. Biočina, "Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting", American Journal of Cardiology, vol. 113, br. 10, str. 1660-1667, Svibanj 2014. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:020711. [Citirano: 26.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:020711
Podaci o radu
Naslov (engleski)Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting
AutorHrvoje Gašparović
AutorMate Petričević
AutorTomislav Kopjar
AutorŽeljko Đurić
AutorLucija Svetina
AutorBojan Biočina
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Coronary artery bypass grafting is pivotal in the contemporary management of complex coronary artery disease. Interpatient variability to antiplatelet agents, however, harbors the potential to compromise the revascularization benefit by increasing the incidence of adverse events. This study was designed to define the impact of dual antiplatelet therapy (dAPT) on clinical outcomes among aspirin-resistant patients who underwent coronary artery surgery. We randomly assigned 219 aspirin-resistant patients according to multiple electrode aggregometry to receive clopidogrel (75 mg) plus aspirin (300 mg) or aspirin-monotherapy (300 mg). The primary end point was a composite outcome of all-cause death, nonfatal myocardial infarction, stroke, or cardiovascular hospitalization assessed at 6 months postoperatively. The primary end point occurred in 6% of patients assigned to dAPT and 10% of patients randomized to aspirin-monotherapy (relative risk 0.61, 95% confidence interval 0.25 to 1.51, p = 0.33). No significant treatment effect was noted in the occurrence of the safety end point. The total incidence of bleeding events was 25% and 19% in the dAPT and aspirin-monotherapy groups, respectively (relative risk 1.34, 95% confidence interval 0.80 to 2.23, p = 0.33). In the subgroup analysis, dAPT led to lower rates of adverse events in patients with a body mass index >30 kg/m(2) (0% vs 18%, p <0.01) and those <65 years (0% vs 10%, p = 0.02). In conclusion, the addition of clopidogrel in patients found to be aspirin resistant after coronary artery bypass grafting did not reduce the incidence of adverse events, nor did it increase the number of recorded bleeding events. dAPT did, however, lower the incidence of the primary end point in obese patients and those <65 years.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaAmerican Journal of Cardiology
Brojčani podacivol. 113, br. 10, str. 1660-1667
p-ISSN0002-9149
DOIhttps://doi.org/10.1016/j.amjcard.2014.02.024
URN:NBNurn:nbn:hr:105:020711
Datum objave publikacije2014-05-15
URL dokumentahttps://doi.org/10.1016/j.amjcard.2014.02.024
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-27 20:16:20